Symbiotec Pharmalab Initial Public Offering Day 2: Subscription Status, Price Band Rs 938 to 988 and Key Dates for August 25, 2026

Symbiotec Pharmalab Initial Public Offering Day 2: Where Things Stand

Today is Day 2 of 4 subscription days for the Symbiotec Pharmalab initial public offering. The issue opened on August 24, 2026 and will close on August 27, 2026. Day 2 typically shows early institutional and HNI (High Net Worth Individual) activity as larger investors begin placing their bids, while QIBs (Qualified Institutional Buyers) tend to submit bids primarily on Day 3 (the final day) of a subscription window. The Symbiotec Pharmalab initial public offering subscription data for Day 2 will be available on the BSE and NSE exchange portals throughout the day.

Parameter	Detail
Issue Name	Symbiotec Pharmalab Initial Public Offering
Day 2 Date	August 25, 2026 (Today)
IPO Open Date	August 24, 2026
IPO Close Date	August 27, 2026 (August 27)
Price Band	Rs 938 to 988 per share
Lot Size	15 shares
Minimum Investment (Retail)	Rs 14,820
Issue Size	Rs 1,757 crore
Exchange	BSE and NSE
Allotment Date	August 28, 2026
Listing Date	September 1, 2026
Registrar	MUFG Intime India

Click Here and Get Free Investment Predictions

How to Apply on Day 2 of Symbiotec Pharmalab Initial Public Offering

If you have not yet applied and have reviewed the company's financials and risk factors from the Red Herring Prospectus (RHP), today is a good day to submit your application. Apply through your Demat account using ASBA or UPI payment on any SEBI-registered broker platform. Select the Symbiotec Pharmalab initial public offering in the IPO section, bid at the cut-off price (Rs 988 upper band) or within the price band, and confirm via UPI block or ASBA mandate. Applying at the cut-off price maximises allotment probability.

Day 2 applications are equally valid as Day 1 applications. There is no advantage to applying on any specific day within the subscription window, as allotment is determined after the subscription closes and all bids are processed simultaneously.

Screen Pharmaceuticals and Biotechnology Sector Peers on Univest for Valuation Context

Business Overview

Symbiotec Pharmalab is a research and development-driven pharmaceutical and biotechnology company and a global leader in steroidal-hormone and corticosteroid active pharmaceutical ingredients (APIs) by volume. It has capabilities across complex injectables, organic chemistry, and biotechnology platforms. Full financial details, promoter background, objects of the issue, and risk factors are available in the Symbiotec Pharmalab initial public offering Red Herring Prospectus filed with SEBI on the EDGAR portal. Review the RHP thoroughly before deciding to subscribe on Day 2 or on the remaining days before August 27, 2026.

Grey Market Premium: What Investors Should Know

A Grey Market Premium (GMP) may appear on unofficial platforms like IPOWatch or Investorgain. GMP is unofficial, not sanctioned by SEBI, and is frequently an inaccurate predictor of actual listing prices. Day 2 GMP figures can change significantly through the remaining subscription days and should never be the primary basis for a subscription decision. Always evaluate this issue on the basis of the company's fundamentals from the RHP.

Download the Univest iOS App or Univest Android App to track Symbiotec Pharmalab subscription status and allotment updates live.

Conclusion: Symbiotec Pharmalab Initial Public Offering Day 2

Day 2 of the Symbiotec Pharmalab initial public offering is underway today. The issue closes on August 27, 2026. Price band is Rs 938 to 988 with a lot size of 15 shares. Allotment is expected on August 28, 2026 and listing on BSE and NSE is expected on September 1, 2026. GMP is unofficial; evaluate the issue on fundamentals from the RHP. Consult a SEBI-registered investment adviser before applying.

Frequently Asked Questions

What day is the Symbiotec Pharmalab initial public offering on August 25?

Ans. August 25 is Day 2 of 4 subscription days for this issue. The issue opened on August 24, 2026 and closes on August 27, 2026. Allotment is expected on August 28, 2026 and listing on BSE and NSE on September 1, 2026.

Can I still apply for the issue on Day 2?

Ans. Yes, you can still apply on Day 2 today. The subscription window remains open until August 27, 2026. Apply through your Demat account using ASBA or UPI on any SEBI-registered broker platform. Day 2 applications are equally valid as Day 1.

What is this issue price band?

Ans. This issue price band is Rs 938 to 988 per share. The lot size is 15 shares with a minimum investment of Rs 14,820 for retail investors.

What is this issue allotment date?

Ans. This issue allotment is expected to be finalised on August 28, 2026. Shares will be credited to successful applicants' Demat accounts within 1 to 2 business days.

What is this issue listing date?

Ans. Shares are expected to list on BSE and NSE on September 1, 2026. The actual listing price on the exchange on that date is the only valid reference for post-allotment decisions.

Is there a GMP for the issue on Day 2?

Ans. GMP for this issue may appear on unofficial platforms like IPOWatch or Investorgain. GMP is not sanctioned by SEBI and is frequently inaccurate as a predictor of listing prices. Do not base your subscription decision on Day 2 GMP. Evaluate using the company's fundamentals from the RHP.

What is Symbiotec Pharmalab's business?

Ans. Symbiotec Pharmalab is a research and development-driven pharmaceutical and biotechnology company and a global leader in steroidal-hormone and corticosteroid active pharmaceutical ingredients (APIs) by volume. It has capabilities across complex injectables, organic chemistry, and biotechnology platforms. Full details are in the RHP on SEBI EDGAR.